The multinational company KPMG, part of the main group of internationally-expanded enterprises offering audit, assurance, taxation, management consulting, actuarial, corporate finance and legal services, has just issued a special report directed to big pharma companies regarding psychedelics for medical purposes.
The fact that one of the Big Four companies dedicates even a small release on the beneficial impact of psychedelics on health should be seen as a step forward in validating this industry’s potential growth and future projection to major, more traditional investors who might still be hesitant about whether to enter.
